Company Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Andrew J. Hirsch M.B.A. |
Contact Details
Address: 490 Arsenal Way, Suite 120 Watertown, Massachusetts 02472 United States | |
| Phone | (617) 231-0700 |
| Website | c4therapeutics.com |
Stock Details
| Ticker Symbol | CCCC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001662579 |
| CUSIP Number | 12529R107 |
| ISIN Number | US12529R1077 |
| Employer ID | 47-5617627 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew J. Hirsch M.B.A. | Chief Executive Officer, President and Director |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Dr. Stewart Fisher | Chief Scientific Officer |
| Scott N. Boyle M.B.A., Ph.D. | Chief Business Officer |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Kendra Adams | Chief Financial Officer |
| Mark Mossler | Chief Accounting Officer |
| Jolie M. Siegel J.D. | Chief Legal Officer and Corporate Secretary |
| Kelly A. Schick | Chief People Officer |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |